Jade Biosciences, Inc.
JBIO evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for JBIO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · JBIO
Jade Biosciences, Inc. (JBIO) is a preclinical-stage biotechnology company focused on developing a pipeline of product candidates, including JADE101, JADE201, and JADE301, with no approved products or revenue to date.
Key risk: No approved products or revenue
BioSniper Score
Based on 5 of 6 signals
Market Cap
$1.33B
Cash Runway
30.7 moLead Asset
av-101 (Preclinical)Next Catalyst
Phase2_Topline · Dec 31, 2026Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 4 clinical trials · 1 catalyst for Jade Biosciences, Inc..
Jade Biosciences, Inc. (JBIO) is a preclinical-stage biotechnology company focused on developing a pipeline of product candidates, including JADE101, JADE201, and JADE301, with no approved products or revenue to date.
- Jade Biosciences is a preclinical-stage biotechnology company with no approved products or revenue from product sales [sec_mda · as of 2026-05-07].
- As of June 30, 2026, the company reported cash and equivalents of $107.2M, net income of -$55.8M, and shareholders' equity of $332.5M [sec].
- The company's pipeline includes JADE101 (Phase 2 topline data expected by December 31, 2026), JADE201 (interim data expected in 2027), and JADE301 (Phase 1 initiation expected in first half of 2027) [sec_mda · as of 2026-05-07].
- As of March 31, 2026, the company had an accumulated deficit of $214.8 million and used $24.1 million in net cash for operating activities in the three months ended March 31, 2026 [sec_mda · as of 2026-05-07].
- The company expects to continue incurring significant expenses as it advances its pipeline, seeks regulatory approvals, and potentially commercializes its product candidates [sec_mda · as of 2026-05-07].
What works
- The company has a pipeline of three product candidates (JADE101, JADE201, JADE301) targeting multiple indications, providing multiple shots on goal [sec_mda · as of 2026-05-07].
- JADE101 is in Phase 2 with a topline data readout expected by the end of 2026, representing a near-term potential catalyst [sec_mda · as of 2026-05-07].
- The company has raised significant capital, including $205 million from a Pre-Closing Financing in 2025 and approximately $135 million from a Private Placement in October 2025, supporting its development activities [sec_mda · as of 2025-11-14].
What to weigh
- The company is preclinical-stage with no approved products and no revenue from product sales, relying entirely on external financing to fund operations [sec_mda · as of 2026-05-07].
- As of March 31, 2026, the company had an accumulated deficit of $214.8 million and used $24.1 million in net cash for operating activities in the three months ended March 31, 2026, indicating a high cash burn rate [sec_mda · as of 2026-05-07].
- The company expects to continue incurring significantly increased expenses for the foreseeable future, and its funding requirements depend on numerous factors including clinical trial progress and regulatory outcomes [sec_mda · as of 2026-05-07].
- There is no guarantee that any product candidate will successfully complete clinical development or obtain regulatory approval, and the company may never generate product revenue [sec_mda · as of 2025-11-14].
From the filings
Quoted directly from source documents.
The company has no approved products and no revenue from product sales.
“We do not have any products approved for sale and have not generated any revenue from product sales.”
SEC MD&A · May 7, 2026
JADE101 Phase 2 topline data expected by end of 2026.
“6, and we expect interim data in 2027.”
SEC MD&A · May 7, 2026
Accumulated deficit of $214.8 million as of March 31, 2026.
“of March 31, 2026, we had an accumulated deficit of $214.8 million.”
SEC MD&A · May 7, 2026
Cash used in operating activities was $24.1 million for the three months ended March 31, 2026.
“For the three months ended March 31, 2026, we used net cash of $24.1 million for our operating activities.”
SEC MD&A · May 7, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline · jade101 — Phase 2 Readout: jade101 — Topline data from the Phase 2 trial of JADE101 is expected by this date, which will be a key value inflection point for the program.
Risks & what to watch (4)›
Key risks
- No approved products or revenue — The company has no products approved for sale and has not generated any revenue from product sales [sec_mda · as of 2026-05-07].
- Significant accumulated deficit and cash burn — As of March 31, 2026, accumulated deficit was $214.8 million and net cash used in operating activities was $24.1 million for the quarter [sec_mda · as of 2026-05-07].
- Dependence on clinical and regulatory success — The company may never obtain regulatory approval for any product candidate and will not generate revenue unless clinical development is successful [sec_mda · as of 2025-11-14].
- Need for additional financing — The company expects to incur significantly increased expenses and will need additional funding to complete development and commercialization [sec_mda · as of 2026-05-07].
What to watch
- Phase 2 topline data for JADE101 expected by December 31, 2026 [sec_mda · as of 2026-05-07].
- Interim data for JADE201 expected in 2027 [sec_mda · as of 2026-05-07].
- Initiation of Phase 1 clinical trial for JADE301 expected in first half of 2027 [sec_mda · as of 2026-05-07].
- Cash runway and potential need for additional financing as the company advances its pipeline [sec_mda · as of 2026-05-07].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Jade Biosciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Jade Biosciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
30.7 months
D/E 0.07 · 0% dilution
Lead: Phase 2
4 candidates
1 upcoming, next in ~123d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
118
Total value held
$625.0M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 7,085,423 | $99.6M |
| janus henderson group plc | 6,211,338 | $87.1M |
| avidity partners management lp | 2,801,416 | $53.9M |
| ra capital management, l.p. | 3,671,083 | $51.6M |
| vanguard capital management llc | 3,593,304 | $50.5M |
| blackrock, inc. | 2,313,949 | $32.5M |
| baker bros. advisors lp | 1,641,137 | $23.1M |
| versant venture management, llc | 1,525,820 | $21.4M |
| samsara biocapital, llc | 968,798 | $13.6M |
| great point partners llc | 964,462 | $13.6M |
Showing top 10 of 118 institutional holders of Jade Biosciences, Inc.. Open the full 13F history after sign-in.
Governance
Frequently asked questions
What is the AI investment thesis for Jade Biosciences, Inc.?
Jade Biosciences, Inc. (JBIO) is a preclinical-stage biotechnology company focused on developing a pipeline of product candidates, including JADE101, JADE201, and JADE301, with no approved products or revenue to date.
What is Jade Biosciences, Inc.'s lead drug candidate?
Jade Biosciences, Inc.'s most advanced tracked candidate is av-101 (Preclinical) for pulmonary arterial hypertension.
What is Jade Biosciences, Inc.'s next catalyst?
Jade Biosciences, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: jade101" — expected December 31, 2026.
Who is the CEO of Jade Biosciences, Inc.?
Mr. Tom Frohlich is the chief executive officer of Jade Biosciences, Inc. (JBIO).
Where is Jade Biosciences, Inc. headquartered?
Jade Biosciences, Inc. (JBIO) is headquartered in Waltham, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.